This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Overactive Bladder
and you are
between 20 and 80
years old
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

1. Primary Objective: To evaluate the dose-response relationship of tarafenacin on efficacy. 2. Secondary Objectives: - To compare 12 weeks' efficacy of different doses of tarafenacin to that of placebo in patients suffering from Overactive Bladder. . - To compare the tolerability of different doses of tarafenacin to that of placebo in patients suffering from Overactive Bladder. .

Provided treatments

  • Drug: Tarafenacin 0.2 mg
  • Drug: Placebo
  • Drug: Tarafenacin 0.4 mg

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01458197. The sponsor of the trial is Kwang Dong Pharmaceutical co., ltd. and it is looking for 235 volunteers for the current phase.
Official trial title:
A Prospective, Multi-center, Placebo-controlled, Randomized, Double-blind, Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo Administered as Oral Daily Dose for Three Months in Patients Suffering From Overactive Bladder.